Demographics of the study population
| Characteristic . | 0 DPB1 mismatch, n = 848 . | 1 DPB1 mismatch, n = 3205 . | 2 DPB1 mismatches, n = 1876 . |
|---|---|---|---|
| CMV status, p/d, no (%) | |||
| Positive/positive | 147 (17) | 544 (17) | 371 (20%) |
| Positive/negative | 220 (26) | 791 (25) | 485 (26%) |
| Negative/positive | 138 (16) | 516 (16) | 265 (14%) |
| Negative/negative | 261 (31) | 1045 (33) | 584 (31%) |
| Unknown | 82 (10) | 309 (10) | 171 (9%) |
| Sex, p/d | |||
| Female/female | 178 (21) | 614 (19) | 358 (19) |
| Female/male | 191 (23) | 698 (22) | 402 (21) |
| Male/female | 147 (17) | 620 (19) | 381 (20) |
| Male/male | 305 (36) | 1154 (36) | 658 (35) |
| Unknown | 27 (3) | 119 (4) | 77 (4) |
| Diagnosis* | |||
| ALL | 172 (20) | 643 (21) | 428 (23) |
| AML | 210 (25) | 775 (24) | 474 (25) |
| CML | 332 (39) | 1260 (39) | 694 (37) |
| MDS | 84 (10) | 350 (11) | 171 (9) |
| Other | 33 (4) | 130 (4) | 70 (4) |
| Unknown | 18 (2) | 48 (1) | 39 (2) |
| Disease severity† | |||
| High | 158 (19) | 672 (21) | 374 (20) |
| Intermediate | 380 (45) | 1458 (45) | 887 (47) |
| Low | 252 (30) | 849 (26) | 488 (26) |
| Unknown | 58 (7) | 226 (7) | 127 (7) |
| T-cell depletion | |||
| Yes | 163 (19) | 604 (19) | 386 (21) |
| No | 647 (76) | 2446 (76) | 1402 (75) |
| Unknown | 38 (4) | 155 (5) | 88 (5) |
| HLA matching‡ | |||
| Matched | 470 (55) | 1461 (46) | 773 (41) |
| Single mismatch | 180 (21) | 866 (27) | 515 (27) |
| Two or more mismatches | 198 (23) | 878 (27) | 588 (31) |
| Source of stem cells | |||
| Bone marrow | 734 (87) | 2775 (87) | 1657 (88) |
| PBMCs | 94 (11) | 347 (11) | 166 (9) |
| Unknown | 20 (2) | 83 (3) | 53 (3) |
| Patient age | |||
| 0th percentile | <1 | <1 | <1 |
| 25th percentile | 18 | 19 | 17 |
| 50th percentile | 34 | 34 | 32 |
| 75th percentile | 45 | 44 | 43 |
| 100th percentile | 68 | 69 | 70 |
| Characteristic . | 0 DPB1 mismatch, n = 848 . | 1 DPB1 mismatch, n = 3205 . | 2 DPB1 mismatches, n = 1876 . |
|---|---|---|---|
| CMV status, p/d, no (%) | |||
| Positive/positive | 147 (17) | 544 (17) | 371 (20%) |
| Positive/negative | 220 (26) | 791 (25) | 485 (26%) |
| Negative/positive | 138 (16) | 516 (16) | 265 (14%) |
| Negative/negative | 261 (31) | 1045 (33) | 584 (31%) |
| Unknown | 82 (10) | 309 (10) | 171 (9%) |
| Sex, p/d | |||
| Female/female | 178 (21) | 614 (19) | 358 (19) |
| Female/male | 191 (23) | 698 (22) | 402 (21) |
| Male/female | 147 (17) | 620 (19) | 381 (20) |
| Male/male | 305 (36) | 1154 (36) | 658 (35) |
| Unknown | 27 (3) | 119 (4) | 77 (4) |
| Diagnosis* | |||
| ALL | 172 (20) | 643 (21) | 428 (23) |
| AML | 210 (25) | 775 (24) | 474 (25) |
| CML | 332 (39) | 1260 (39) | 694 (37) |
| MDS | 84 (10) | 350 (11) | 171 (9) |
| Other | 33 (4) | 130 (4) | 70 (4) |
| Unknown | 18 (2) | 48 (1) | 39 (2) |
| Disease severity† | |||
| High | 158 (19) | 672 (21) | 374 (20) |
| Intermediate | 380 (45) | 1458 (45) | 887 (47) |
| Low | 252 (30) | 849 (26) | 488 (26) |
| Unknown | 58 (7) | 226 (7) | 127 (7) |
| T-cell depletion | |||
| Yes | 163 (19) | 604 (19) | 386 (21) |
| No | 647 (76) | 2446 (76) | 1402 (75) |
| Unknown | 38 (4) | 155 (5) | 88 (5) |
| HLA matching‡ | |||
| Matched | 470 (55) | 1461 (46) | 773 (41) |
| Single mismatch | 180 (21) | 866 (27) | 515 (27) |
| Two or more mismatches | 198 (23) | 878 (27) | 588 (31) |
| Source of stem cells | |||
| Bone marrow | 734 (87) | 2775 (87) | 1657 (88) |
| PBMCs | 94 (11) | 347 (11) | 166 (9) |
| Unknown | 20 (2) | 83 (3) | 53 (3) |
| Patient age | |||
| 0th percentile | <1 | <1 | <1 |
| 25th percentile | 18 | 19 | 17 |
| 50th percentile | 34 | 34 | 32 |
| 75th percentile | 45 | 44 | 43 |
| 100th percentile | 68 | 69 | 70 |
Data are numbers (%). The self-described patient and donor racial backgrounds were as follows: North American and European, 80.6% and 64.3%; Hispanic, 4.1% and 3.5%; black, 2.8% and 2.3%; Asian, 2.3% and 2.3%; Native American, 0.2% and 0.6%; and other or unknown, 9.9% and 26.9%.
p/d indicates patient/donor; and PBMCs, peripheral blood mononuclear cells.
The ″other″ category included both malignant and nonmalignant diagnoses: aplastic anemia, acute leukemia undifferentiated, chronic leukemia, chronic lymphocytic leukemia, chronic myelomonocytic leukemia, Fanconi anemia, hemoglobinopathy, histiocytic disorder, Hodgkin lymphoma, inherited disorder of metabolism, malignant other, multiple myeloma, myeloproliferative syndrome, non-Hodgkin lymphoma, nonmalignant other, other acute leukemia, other leukemia, plasma cell disorder, severe combined immunodeficiency and other immune system disorders, secondary acute leukemia, and thalassemia.
Low-risk indicates CML chronic phase; intermediate-risk, CML accelerated phase or blast crisis/remission, acute leukemia with transplantation in remission, and MDS–refractory anemia; high-risk, blast-crisis CML, acute leukemia with transplantation in relapse, and MDS other than refractory anemia.
HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1.